Valneva SE (VALN) Liabilities and Shareholders Equity (2020 - 2026)

Valneva SE's (VALN) quarterly Liabilities and Shareholders Equity came in at $435.5 million in Q1 2026, down 14.14% year-on-year from $507.3 million in Q1 2025, and down 6.19% quarter-over-quarter from $464.3 million in Q4 2025.

Valneva SE (VALN) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

Valneva SE has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $435.5 million for Q1 2026.

  • Liabilities and Shareholders Equity for Q1 2026 came in at $435.5 million, down 14.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 billion (down 7.23% YoY), and the FY2025 annual result was $464.3 million, down 13.11% from the prior year.
  • Liabilities and Shareholders Equity came in at $435.5 million for Q1 2026 at Valneva SE, down from $464.3 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $872.9 million in Q1 2022 to a low of $435.5 million in Q1 2026.
  • The 5-year median for Liabilities and Shareholders Equity is $546.3 million (2024), against an average of $581.6 million.
  • Across the five-year window, Liabilities and Shareholders Equity sank 32.2% in 2022 and rose 7.95% in 2024, its largest moves.
  • Valneva SE's Liabilities and Shareholders Equity stood at $633.9 million in 2022, then fell by 21.92% to $495.0 million in 2023, then grew by 7.95% to $534.3 million in 2024, then dropped by 13.11% to $464.3 million in 2025, then decreased by 6.19% to $435.5 million in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $435.5 million (Q1 2026), $464.3 million (Q4 2025), and $524.0 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Alterity Therapeutics 723,416.35 Bn 723,416.32 Bn - 37.37 Mn
2 Belite Bio 57,340.00 Bn 57,340.00 Bn - 811.27 Mn
3 Quantum Biopharma 19,125.08 Bn 19,125.08 Bn - 14.93 Mn
4 Legend Biotech 3,262.00 Bn 3,261.71 Bn 242.10 Mn 1.73 Bn
5 Akari Therapeutics 1,789.67 Bn 1,789.67 Bn - 33.89 Mn
6 Evaxion A 1,480.39 Bn 1,480.37 Bn - 23.64 Mn
7 Psyence Biomedical 241.78 Bn 241.78 Bn - 12.81 Mn
8 Vertex Pharmaceuticals 113.54 Bn 106.29 Bn 2.59 Bn 26.48 Bn
9 Abivax 94.26 Bn 94.26 Bn - 640.56 Mn
10 Valneva SE 167.33 Mn 44.10 Mn 5.08 Mn 435.53 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 435.53 Mn
Dec 31, 2025 464.26 Mn
Sep 30, 2025 524.00 Mn
Jun 30, 2025 534.99 Mn
Mar 31, 2025 507.26 Mn
Dec 31, 2024 534.33 Mn
Sep 30, 2024 567.36 Mn
Jun 30, 2024 502.44 Mn
Mar 31, 2024 546.25 Mn
Dec 31, 2023 495.00 Mn
Sep 30, 2023 566.65 Mn
Jun 30, 2023 590.82 Mn
Mar 31, 2023 633.27 Mn
Dec 31, 2022 633.92 Mn
Sep 30, 2022 703.86 Mn
Jun 30, 2022 773.73 Mn
Mar 31, 2022 872.85 Mn
Dec 31, 2021 935.03 Mn
Dec 31, 2020 535.53 Mn